Emerging evidence from preclinical and biomarker studies indicates that the pathology underlying neurodegenerative diseases begins many years before a clinical diagnosis is apparent.
1,2 In Parkinson disease (PD), the second most common neurodegenerative disorder with a societal cost of more than $15 billion (2010-adjusted) per year in the United States,
3 there is a prodromal phase characterized by pathologic alterations in dopaminergic integrity and subtle nonmotor features in the absence of cardinal motor signs.
1 Earlier detection of PD would enable testing of potential disease-modifying treatments when pathology is less advanced and when treatments may be more effective.
4 Identifying individuals with prodromal PD requires an assessment strategy that is both widely available and highly specific. We describe a sequential biomarker paradigm, starting with a highly sensitive, widely available tool (olfaction) to identify a risk group followed by a highly specific test (dopamine transporter [DAT] imaging) to confirm a high-risk group.